Literature DB >> 6230985

Difference between monoclonal antibodies against the common acute leukemia antigen from two different hybridomas.

C Canon, F Eichler-Reiss, P Reizenstein, G Mathé.   

Abstract

Antibodies directed against the common acute lymphoid leukemia antigen (CALLA) were obtained from 2 hybridomas: J5 (Schlossman, mice sensitized with patient ALL cells), and Vil-A1 (Knapp, sensitization with the Reh cell line). The percentage of lymphoid cells reacting with these 2 monoclonal antibodies were compared. Antibody dilution curves indicated that the dilutions used yielded maximum percentages of positive cells. The percentage of CALLA-positive cells with the J5 antibody was significantly (p less than 0.001) higher than that found with the Vil-A1 antibody in 16 non-neoplastic inflammatory tonsils and in 13 non-Hodgkin lymphoma and chronic lymphatic leukemia lymph-nodes (p less than 0.05). In contrast, the difference between CALLA positive cells with J5 and Vil-A1 was not significant (p greater than 0.5) in 19 acute lymphoid leukemias. The difference between the ALL-cells, presumably pre-B, and the B-cells from the non-ALL subjects was also statistically significant (p less than 0.01). The results suggest that the two hybridomas form antibodies against different CALLA epitopes. Vil-A1 seems somewhat more specific for ALL than J5.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6230985

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Influence of pre-incubation with one antibody on the binding of a second by human lymphocytes.

Authors:  F Eichler-Reiss; P Reizenstein; G Mathé
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

2.  Cytotoxicity of monoclonal antibodies against individually immunophenotyped human leukemic cells.

Authors:  M Beksac; A Porwit-Ksiazek; R Hast; P Biberfeld; P Reizenstein
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.